Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy.
BACKGROUND
Emtricitabine/rilpivirine/tenofovir (EVP) is a fixed-dose combination of antiretrovirals (ARV) approved by the European Medicines Agency in November 2011 and introduced in Italy in February 2013. It is a once-a-day single tablet and is licensed in Europe for use only in ARV-naïve patients with a viral load (VL) ≤100,000 copies/mL.


OBJECTIVE
To identify factors that may be associated with the use of EVP as first-line regimen in HIV-infected individuals starting cART from ARV-naïve in Italy.


METHODS
Clinical sites in ICONA Foundation Study in which ≥1 person had started EVP were selected for this analysis. From these we included all patients who started an EVP-based cART regimen as well as those starting other cART regimens after the date of introduction of EVP at the site (after February 2013 in any case) and with a VL ≤100,000 copies/mL from ARV-naïve. Characteristics at the time of starting cART were compared using chi-square test and unadjusted and adjusted logistic regression analysis. Factors investigated included: gender, mode of HIV transmission, time from HIV diagnosis, CD4 count, nation of birth, AIDS, HCV-status, age, CD8 count, VL, diabetes, smoking, total and HDL cholesterol, eGFR, blood glucose, level of education and employment and site location. Factors showing unadjusted associations with a p-value of 10% or smaller, were retained in the multivariable model.


RESULTS
We identified 183 patients starting EVP and 173 starting the control regimen from 23 sites. The number of patients starting EVP included at each site ranged from 1 to 12 and the number of those starting the control regimen was similar. The most frequently used drugs in the concurrent group were: TDF (75%), FTC (74%), DRV (39%), ATV/r (26%), LPV/r (9%), EFV (13%) and RAL (14%). In univariable analysis, there were differences in median CD4 count (390 cells/mm(3) in EVP versus 348 in controls, p=0.002), time from HIV diagnosis to starting cART (11 versus 3 months, p=0.001) and prevalence of students (6% versus 3%, p=0.07). No differences were observed for all other factors examined. The table shows estimates of the odds ratios (OR) for factors included in the multivariable model.


CONCLUSIONS
CD4 count was higher in EVP-treated patients compared to controls. Guidelines suggest avoiding initiation of EVP in presence of high VL, possibly explaining this residual difference in CD4. There was also a tendency to prescribe EVP to people with perceived lower adherence or hesitant to start or perhaps with a slow progressing disease.
Infection and Population Health, University College London, London, Italy.
Alessandro
A
Cozzi-Lepri
Infectious Diseases Clinic, S. M. Annunziata Hospital, Firenze, Italy.
Sergio
S
Lo Caputo
Infectious Diseases, Ospedali Riuniti Bergamo, Bergamo, Italy.
Franco
F
Maggiolo
Infectious Diseases, INMI Spallanzani Hospital, Rome, Italy.
Andrea
A
Antinori
Infectious Diseases, INMI Spallanzani Hospital, Rome, Italy.
Adriana
A
Ammassari
Health Sciences, San Paolo Hospital, Milan, Italy.
Giulia
G
Marchetti
Infectious Disease, La Sapienza University Rome, Rome, Italy.
Claudio
C
Mastroianni
Infectious Diseases, San Gerardo University Monza, Monza, Italy.
Andrea
A
Gori
Infectious Diseases, University of Turin, Turin, Italy.
Giovanni
G
Di Perri
Biomedical Sciences, University of Bari, Bari, Italy.
Gioacchino
G
Angarano
Infectious Diseases, San Raffaele Hospital, Milan, Italy.
Alessia
A
Carbone
Health Sciences, San Paolo Hospital, Milan, Italy.
Antonella d'Arminio
Ad
Monforte